Gene Test May Improve BC Treatment
Gene Test May Improve Breast Cancer Treatment
70-gene 'signature' gives more accurate prognosis, study finds
WEDNESDAY, Sept. 6 (HealthDay News) -- A test that checks the expression of 70 genes associated with breast cancer can help doctors determine a patient's risk of cancer recurrence or death, an international study finds.
The study included 307 breast cancer patients assigned to high- and low-risk groups based on their scores from the 70-gene signature test and standard risk-assessment using a software program. The patients were followed for 13.6 years.
The gene-signature test was a more accurate predictor of cancer recurrence and death than the software, the researchers found. The study also concluded that the gene test included most of the prognostic information provided by traditional risk classifiers.
"These results indicate that the gene signature adds independent prognostic information," reported scientists at the Netherlands Cancer Institute in Amsterdam.
The findings were published in the Sept. 6 issue of the Journal of the National Cancer Institute.
The 70-gene signature test will be evaluated in a larger study of 6,000 women with node-negative early-stage breast cancer. The trial will assess whether the test can improve identification of women who can safely be spared adjuvant chemotherapy.
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
|